The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Current pharmacotherapy for allergic rhinitis (AR) does not totally ameliorate all symptoms for all patients. Residual symptoms could be due to nasal neuronal hyperresponsiveness caused by stimulation of the ion channel transient receptor potential vanilloid 1 (TRPV1). SB-705498 is a TRPV1 antagonist that has been developed in an intranasal formulation for treatment of AR. METHODS: This randomized, double-blind, 3-way incomplete block crossover study evaluated the effects of 8 days treatment with SB-705498 12 mg alone, SB-705498 12 mg plus fluticasone propionate 200 μg (FP), FP 200 μg alone or placebo on allergen-induced symptoms in 70 patients with AR. The primary endpoint was total nasal symptom score (TNSS), expressed as mean over 4 hours or maximum TNSS during allergen challenge in the Vienna Challenge Chamber on 8th day of treatment. RESULTS: At the end of treatment, there were no differences in allergen-induced mean TNSS between SB-705498 alone and placebo or between SB-705498 plus FP and FP alone. Treatment with FP and SB-705498 plus FP resulted in a significant decrease in TNSS vs. placebo. Mean (90% CI) treatment differences in TNSS over 0 - 4 hours were: SB-705498 - placebo: -0.2 (-0.9, 0.4); SB-705498 plus FP - FP: 0.7 (0.2, 1.2); FP - placebo: -2.9 (-3.4, -2.5); SB-705498 plus FP - placebo: -2.3 (-2.8, -1.8). SB-705498 had no impact on diary card symptoms, nasal airflow or Rhinoconjunctivitis Quality of Life Questionnaire scores. SB-705498 was well tolerated and pharmacokinetics exposure results supported the dosing regimen. CONCLUSION: SB-705498 12 mg for 8 days did not alleviate the allergen-induced symptoms of AR, or provide additional relief of symptoms when in combination with FP. Despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this respect, numerous randomized, placebo-controlled clinical trials have been conducted using parallel-group or crossover designs in order to test the efficacy of drugs with immediate therapeutic activity, such as antihistamines,1050-1053 or with prophylactic therapeutic potential, such as topical steroids,1054-1056 novel anti-inflammatory compounds,1057-1060 or probiotics.1061”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1057]
Citations
Cites
Naclerio, R. M. (2003) · Cited by 985
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire☆☆☆★
Juniper, E. F., Thompson, A. K., Ferrie, P. J., & Roberts, J. N. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70380-5 · Cited by 376
The role of the nervous system in rhinitis
Sarin, S., Undem, B., Sanico, A., & Togias, A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.013 · Cited by 245
Interpretation of rhinoconjunctivitis quality of life questionnaire data
Juniper, E. F., Guyatt, G. H., Griffith, L. E., & Ferrie, P. J. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70135-5 · Cited by 244
Allergic rhinitis: Direct and indirect costs
Blaiss, M. S. (2010) · Allergy and Asthma Proceedings · doi:10.2500/aap.2010.31.3329 · Cited by 220
The transient receptor potential vanilloid 1: Role in airway inflammation and disease
Geppetti, P., Materazzi, S., & Nicoletti, P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.063 · Cited by 187
Allergic rhinitis and the common cold – high cost to society
Hellgren, J., Cervin, A., Nordling, S., Bergman, A., & Cardell, L. O. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02269.x · Cited by 183
International Primary Care Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis
Price, D. B., Bond, C. M., Bouchard, J., Costa, R., Keenan, J. M., Levy, M. L., Orru, M., Ryan, D. P., Walker, S. M., & Watson, M. C. (2005) · Primary Care Respiratory Journal · doi:10.1016/j.pcrj.2005.11.002 · Cited by 133
Allergic rhinitis and impairment issues in schoolchildren: a consensus report
Group, M. S. B. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x13266 · Cited by 132
Horak, F., Stübner, U. P., Zieglmayer, R., & Harris, A. G. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.124657 · Cited by 111
Self-citation
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Nilius, B., & Szallasi, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008268 · Cited by 506
“9) did not provide any symptomatic relief in patients with seasonal allergic rhinitis (Bareille et al., 2013).”
BackgroundAdverse Effects of Cigarette and Noncigarette Smoke Exposure on the Autonomic Nervous System
Middlekauff, H. R., Park, J., & Moheimani, R. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1201 · Cited by 240
Khalid, S., Murdoch, R., Newlands, A., Smart, K., Kelsall, A., Holt, K., Dockry, R., Woodcock, A., & Smith, J. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.038 · Cited by 194
Self-citationGarami, A., Shimansky, Y. P., Rumbus, Z., Vizin, R. C. L., Farkas, N., Hegyi, J., Szakacs, Z., Solymar, M., Csenkey, A., Chiche, D. A., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107474 · Cited by 159
Involvement of Neural Transient Receptor Potential Channels in Peripheral Inflammation
Silverman, H. A., Chen, A., Kravatz, N. L., Chavan, S. S., & Chang, E. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590261 · Cited by 167
TRP Channel Cooperation for Nociception: Therapeutic Opportunities
Bamps, D., Vriens, J., Hoon, J. N. J. M. D., & Voets, T. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023238 · Cited by 120
Sun, S., & Dong, X. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0530-4 · Cited by 95
“Intranasal SB-705498 attenuated capsaicin driven nasal hyper-reactivity in non-allergic rhinitis [160], but had only limited effect in treating symptoms of allergic rhinitis symptoms [161].”
The role of TRPV1 in the CD4+ T cell-mediated inflammatory response of allergic rhinitis
Samivel, R., Kim, D. W., Son, H. R., Rhee, Y., Kim, E. H., Kim, J. H., Bae, J.-S., Chung, Y., Chung, P., Raz, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6653 · Cited by 59
Current recommendations and emerging options for the treatment of allergic rhinitis
Licari, A., Ciprandi, G., Marseglia, A., Castagnoli, R., Barberi, S., Caimmi, S. M. E., & Marseglia, G. L. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.955476 · Cited by 43
“Unfortunately, a highly selective and potent intranasal formulation of a TRPV1 antagonist (SB-705498) failed to demonstrate its clinical efficacy, suggesting a redundant mechanism of action for this class of compounds [72].”
BackgroundNeuropathic Pain and Itch Mechanisms Underlying Allergic Conjunctivitis
Kuruvilla, M. E., Kalangara, J. P., & Lee, F. E.-H. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0320 · Cited by 40
“However, in subjects with allergic rhinitis, an intranasal TRPV1 antagonist alone or combined with fluticasone propionate did not improve allergen-induced symptoms [49].”
BackgroundSIRT6 as a potential target for treating insulin resistance
Tang, W., & Fan, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116558 · Cited by 35
Epithelial and sensory mechanisms of nasal hyperreactivity
Velasco, E., Delicado‐Miralles, M., Hellings, P. W., Gallar, J., Gerven, L. V., & Talavera, K. (2022) · Allergy · doi:10.1111/all.15259 · Cited by 41
Transient Receptor Potential Channels and Itch: How Deep Should We Scratch?
Tóth, B. I., SZALLASI, A., & Bíró, T. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44605-8_6 · Cited by 34
The contribution of ion channels to shaping macrophage behaviour
Selezneva, A. I., Gibb, A. J., & Willis, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970234 · Cited by 36
“Seasonal allergic rhinitis Phase II No effect of antagonist compared to placebo (Bareille et al., 2013)”
BackgroundHigh Throughput Confined Migration Microfluidic Device for Drug Screening
Yang, Z., Zhou, Z., Si, T., Zhou, Z., Zhou, L., Chin, Y. R., Zhang, L. N., Guan, X., & Yang, M. (2023) · Small · doi:10.1002/smll.202207194 · Cited by 37
TRPV1 and TRPM8 in Treatment of Chronic Cough
Millqvist, E. (2016) · Pharmaceuticals · doi:10.3390/ph9030045 · Cited by 34
Backaert, W., Steelant, B., Hellings, P. W., Talavera, K., & Gerven, L. V. (2021) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00981-x · Cited by 35
North, M. L., Soliman, M., Walker, T., Steacy, L. M., & Ellis, A. K. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0514-4 · Cited by 30
Allergic rhinitis: current options and future perspectives
Braido, F., Arcadipane, F., Marugo, F., Hayashi, M., & Pawankar, R. (2014) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000043 · Cited by 33
“A recent trial using TRPV1 antagonist in an intranasal formulation did not show any clinical efficacy [84].”
Qiao, Y., Zhang, Y., Qiao, Z., He, W., Chen, Y., Song, D., Wang, G., Guo, N., Shao, L., Tian, Z., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114191 · Cited by 26
The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Nam, J., & Kim, W. K. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181126113015 · Cited by 27
New Therapies for Allergic Rhinitis
Braido, F., Sclifò, F., Ferrando, M., & Canonica, G. W. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0422-z · Cited by 27
Emerging drugs for the treatment of perennial allergic rhinitis
Licari, A., Castagnoli, R., Bottino, C., Marseglia, A., Marseglia, G. L., & Ciprandi, G. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1139082 · Cited by 25
“clinical efficacy in patients with seasonal AR, suggesting a redundant mediator role for these compounds in the symptom of AR.[95]”
BackgroundXiao, F., Zhou, Y., Liu, Y., Xie, M., & Guo, G. (2019) · Medical Science Monitor · doi:10.12659/msm.917118 · Cited by 20
“It can upregulate TRPV1 channel activity, which induces spontaneous inflammation and nerve injury [40,41].”
BackgroundTrigeminal Function in Sino-Nasal Health and Disease
Shusterman, D. J. (2023) · Biomedicines · doi:10.3390/biomedicines11071778 · Cited by 23
“Of these studies, two involved seasonal allergic rhinitics (neither of which showed significant symptomatic improvement) [145,146].”
BackgroundUpregulation of extraneuronal TRPV1 expression in chronic rhinosinusitis with nasal polyps
Tóth, E., Tornóczky, T., Kneif, J., Perkecz, A., Katona, K., Piski, Z., Kemény, Á., Gerlinger, I., Szolcsányi, J., Kun, J., et al. (2018) · Rhinology Journal · doi:10.4193/rhin17.108 · Cited by 19
Wilson, R. C., Ahmmed, A. A., Poll, A. A., Sakaue, M., Laude, A., & Sieber‐Blum, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199996 · Cited by 20
Robust expression of SIRT6 inhibits pulpitis via activation of the TRPV1 channel
Hu, J., Chen, W., Qiu, Z., & Lv, H. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3528 · Cited by 13
“Capsaicin may also upregulate the activity of TRPV1, which may induce spontaneous inflammation and nerve injury.(26,27) In this study, LPS-induced pulpitis upregulated TRPV1 expression and F IGURE 6 SIRT6 ameliorated LPS-induced pulpitis in vivo.”
BackgroundPersonalized therapies for the treatment of allergic rhinitis
Licari, A., Castagnoli, R., Tosca, M. A., Marseglia, G. L., & Ciprandi, G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1681896 · Cited by 12
Investigational drugs for the treatment of allergic rhinitis
Castillo, J. C. M., & Dimov, V. V. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.907271 · Cited by 13
“Although SB-705498 was well tolerated and pharmacokinetics exposure supported the dosing regimen, there was no translation to clinical efficacy, suggesting redundancy in symptom pathways [78].”
BackgroundRole of oxidative stress & transient receptor potential in chronic obstructive pulmonary disease
Bose, P., Bathri, R., Kumar, L., Vijayan, V. K., & MAUDAR, K. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.166529 · Cited by 10
Lin, Y., Wang, J., Pan, M., Qiu, Q., Huang, W., & Qian, H. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12661 · Cited by 10
Liang, Q., Lv, X., Cai, Q., Cai, Y., Zhao, B., & Li, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01171 · Cited by 10
“This assay was used to re-evaluate whether there was any damage to the cell membranes in the presence of NOVO, CAP, RR, and SB-705498 at the noncytotoxic concentrations determined by the MTT assay.”
InfluentialPhan, H. T. L., Nam, Y.-R., Kim, H. J., Van, N. T. H., Vo, N. T., Woo, J., Kim, J., Nam, J., & Kim, W. K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118460 · Cited by 6
Effect of lower uterine segment sweeping on progress of labor in nullipara.
Chanrachakul, B., Suthutvoravut, S., Sangthawan, M., & Herabutya, Y. (2001) · PubMed · Cited by 7
TRPV1 antagonists: Future drug discovery directions
Ann, J., Blumberg, P. M., & Lee, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18653-0.00022-8 · Cited by 3
TRP Channels, Oxidative Stress and Chronic Obstructive Pulmonary Disease
Mandal, A., Srivastava, A., Chakraborti, T., & Chakraborti, S. (2019) · Springer eBooks · doi:10.1007/978-981-32-9366-3_10 · Cited by 1
SZALLASI, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30202-2.00007-7
Current uses of capsaicin in the clinic
SZALLASI, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30202-2.00010-7
Metadata
- Authors
- Bareille, P., Murdoch, R. D., Denyer, J., Bentley, J., Smart, K., Yarnall, K., Zieglmayer, P., Zieglmayer, R., Lemell, P., & Horak, F.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Medical University of Vienna (AT)
- University of Vienna (AT)
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2013-07-01
- Volume
- 51
- Issue
- 07
- Pages
- 576-584
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2086120371
- Cited by
- 41
- References
- 31
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 6 · 2016: 2 · 2015: 6 · 2014: 7
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- TRPV1 antagonists, allergic rhinitis, fluticasone propionate, nasal symptom score, nasal hyperreactivity, combination therapy, drug tolerability, pharmacokinetics, quality of life, nasal airflow, rhinoconjunctivitis
- MeSH terms
- Fluticasone, Administration, Intranasal, Adult, Androstadienes, Austria, Double-Blind Method, Drug Therapy, Combination, Female, Rhinitis, Allergic, Seasonal, Humans, Male, Pyrrolidines, Urea, Treatment Outcome, Cross-Over Studies, Anti-Allergic Agents, TRPV Cation Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.